Search

Can 3D facial imaging improve patient management in disfiguring eye disease?

Fight for Sight is the leading UK charity funder of eye research. Since the 2013 Sight Loss and Vision Priority Setting Partnership we have encouraged our researchers to work on priorities jointly identified by people affected by sight loss and...

Uveal melanoma

Uveal melanoma is the most common primary intraocular tumour. However, they are still rare, with an incidence of 2-8 per million [1]. The presence of a choroidal naevus is a risk factor for uveal melanoma [1]. Patients with choroidal lesions...

The ocular manifestations of COVID-19: an overview of current literature

Although respiratory symptoms are the most frequent manifestation of COVID-19, multi-organ involvement has been demonstrated, including ocular manifestations. The author investigates how the eye can be affected. The SARS-CoV-2 virus responsible for the COVID-19 pandemic has presented a significant public...

Visual disturbance heralding stroke: are we seeing the signs in time?

Isolated visual symptoms may be an early presenting feature of stroke, and timely recognition of such atypical cases is important because treatment for stroke has a limited time-window of efficacy. Stroke occurs in approximately 150,000 people per year in the...

You want to do paediatric ophthalmology? Seriously?

Completion of Core Training is approaching fast and you begin to wonder three things. One, where do you want to live? Two, is anyone going to be retiring there soon? Three, what subspecialty do you want to do? In an...

Developments in retinal pigmentation measurement and the hopes of an equitable future

Our AI & Oculomics co-editor, Nima Ghadiri, sat down with Abraham Olvera-Barrios from Moorfields and Anand Rajesh from the University of Washington to discuss their recent international study into retinal pigmentation and its wider clinical, technological and academic applications. Can...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...

An update on inherited retinal disorders (part 1) – overview and assessment of inherited retinal disease

Part 2 of this topic can be found here Inherited Retinal Disease (IRD) is the leading cause of blindness certification in the working age population (age 16-64 years) in England and Wales and the second most common in childhood [1]....

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...